Company news
hVIVO plc news in 2021
hVIVO plc's news releases, calls and decks from 2021, newest first.
£5m Influenza human challenge study contract win
December 21, 2021
$13.4m Influenza HCS contract win
December 10, 2021
Positive results from Flu Human Challenge Study
December 6, 2021
Imutex Vaccine Phase I Study Results
November 19, 2021
£5.1m RSV contract
November 17, 2021
£1.5m Contract renewal for Venn Life Sciences
November 15, 2021
Half-year Report
September 20, 2021
£8.1m Asthma Human Challenge Study Contract Win
August 24, 2021
Malaria Human Challenge Model
August 9, 2021
DNDi Phase II trial support
July 29, 2021
NEJM Opinion Piece
July 22, 2021
Directors' Dealings
July 14, 2021
HRV and Flu contract
July 9, 2021
2020 Annual Report and 2021 AGM Notice
June 30, 2021
Demerger Update
June 17, 2021
Re. Distribution in Specie and Notice of Results
June 14, 2021
Court Approval
May 19, 2021
Exercise of Share Options
May 10, 2021
Result of General Meeting
April 29, 2021
Potential demerger of certain non-core assets
April 13, 2021
Launch of Disease in Motion platform
April 9, 2021
£7.5m Human Challenge Study Contract
March 26, 2021
COVID-19 Human Challenge Programme update
March 25, 2021
Journal for Clinical Studies article publication
March 11, 2021
New contract win with Oxford BioTherapeutics
March 9, 2021
Ethics approval - COVID-19 Human Challenge Study
February 17, 2021
Exercise of Investor Warrants & TVR
February 3, 2021
Contract extension with Carna Biosciences
February 1, 2021
Article published in Drug Discovery Today
January 21, 2021
Expansion of volunteer recruitment centres
January 20, 2021
First volunteer dosed in COVID-19 clinical trial
January 11, 2021
Contract renewal with top-3 pharmaceutical client
January 6, 2021